Net Loss Per Share

6 Months Ended

Jun. 30, 2015

10. Net Loss Per Share

Basic and diluted net loss per common share is calculated by dividing net loss applicable to Heat Biologics, Inc. by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company's potentially dilutive shares, which include outstanding stock options, and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following table reconciles net loss to net loss attributable to the Heat Biologics, Inc.:


	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Net loss	$	(4,902,748	)	$	(2,958,357	)	$	(8,929,615	)	$	(5,381,323	)
Net loss: Non-controlling interest		(189,277	)		(111,442	)		(306,946	)		(203,810	)
Net loss attributable to Heat Biologics, Inc.	$	(4,713,471	)	$	(2,846,915	)	$	(8,622,669	)	$	(5,177,513	)

Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.—basic and diluted		8,401,159			6,452,986			7,612,393			6,432,857
Net loss per share attributable to Heat Biologics, Inc.—basic and diluted	$	(0.56	)	$	(0.44	)	$	(1.13	)	$	(0.80	)

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:


	For the Six Months Ended June 30,
	2015		2014
Outstanding stock options		1,044,020		599,486
Common stock warrants		17,392		17,392
Underwriters warrants		125,000		125,000